Document is current

Article History

Received: 7 February 2020

Accepted: 14 February 2020

First Online: 4 March 2020

Competing interests

: None of the members of the organizing committee (F.R., D.E.C., D.H.R. and J.B.D.) and none of the voting members of the expert panel received payment for their participation. Travel expenses for the face-to-face meeting of the expert panel were supported by Medtronic, Ethicon, Novo Nordisk, Fractyl Laboratories, GI Dynamics, Cairn Diagnostics, Keyron, and Aventic Group. C.M.A. has participated on advisory boards for Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, EnteroMedics, GI Dynamics, Gelesis, Novo Nordisk, Bariatrix, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, and Scientific Intake; has received research funding from Aspire Bariatrics, GI Dynamics, Takeda, the Vela Foundation, Gelesis, Energesis, Coherence Lab, and Novo Nordisk; and owns stock in Science-Smart LLC. L.J.A. has received consulting fees from and serves on advisory boards for Jamieson Laboratories, Pfizer, Novo Nordisk, Eisai, Real Appeal, Janssen, and Gelesis; has also received research funding from Aspire Bariatrics, Allurion, Eisai, AstraZeneca, Gelesis, Janssen, Eli Lily, and Novo Nordisk; serves on the board of directors for Intellihealth/BMIQ, MYOS, and Jamieson Laboratories; and has equity in Intellihealth/BMIQ, ERX, Zafgen, Gelesis, MYOS, and Jamieson Laboratories. R.L.B. is a principle investigator for clinical trials funded by Novo Nordisk and Fractyl (all funds go directly to the institution); and has consultancy agreements with Novo Nordisk, Pfizer, GSK, and International Medical Press. C.B. is a principal investigator on a study of metabolic surgery funded by Prodigies; and has received fees from Ethicon Endosurgery. B.L. is on the Scientific Advisory Board of Novo Nordisk; has received speaker fees from Bruno Farmaceutici; and has a research grant from Enzymmanagemen. D.E.C. is on the Scientific Advisory Boards of G.I. Dynamics, DyaMx, Magnamosis, and Metavention. J.B.D. has consultancies with Bariatric Advantage, iNova, and Reshape; is on advisor boards for Novo Nordisk and Nestlé Health Science; and receives research support from NHMRC. M.deG. has received funds from Lifescan Diabetes Institute, Inc., and the Kenner Family Foundation. R.H.E. has received funds from Amgen, Kowa, Sanofi, and Novo Nordisk. S.W.F. has received from Novo Nordisk for travel; and support for working with media. L.M.K. has received funds from Boehringer Ingelheim, Ethicon, Gelesis, GI Dynamics, Johnson & Johnson, Pfizer, Novo Nordisk, and Rhythm Pharmaceuticals. J.P.K. has received grants and research support from the National Institutes of Health, Ethicon, Covidien, Metagenics, Alliance for Potato Research and Education, CrossFit, Nestlé Research, General Mills, and Robard Corporation; is on advisory panels for Bristol-Myers Squibb, AstraZeneca, Novo Nordisk, and Cereal Partners; and receives speaker fees from Elli Lilly, Pfizer, and ILSI. J.K. is on the scientific advisory board of Digma Medical, GI Dynamics, and Applied Biosciences; and consults for Esquagama. T.K.K. has received consulting fees from Tivity Health, Novo Nordisk, and Gelesis. C.W.leR. is on the advisory boards and speaker bureaus for NovoNordisk, GI Dynamics, Keyron, Herbalife, Sanofi, Johnson & Johnson, Medtronic, and Boehringer Ingelheim; and owns shares in Keyron. J.I.M. has received honoraria for lectures and program development from Abbott Nutrition. G.M. has received fees for consultations from Novo Nordisk, Johnson & Johnson, and Fractyl Inc. J.N. is an employee of the Obesity Action Coalition. R.M.P. has received research grant support from the Rudd Foundation, and WW, Inc. F.R. is on advisory boards for GI Dynamics, Keyron, and NovoNordisk; has received consulting fees from Ethicon Endosurgery and Medtronic; and has received research funding from Ethicon Endosurgery and Medtronic. D.H.R. has an equity interest in start-up companies engaged in various aspects of weight management (Gila Therapeutics, Scientific Intake, Xeno Biosciences, Epitomee, and Calibrate); is on the Speaker’s Bureau of Novo Nordisk and Bausch Health; has served as an advisor or consultant to Alyvent, Amgen, Bausch Health, Boehringer Ingelheim, Epitomee, Gila Therapeutics, IFA Celtic, Janssen, Kensai Therapeutics, Novo Nordisk, Phenomix, Real Appeal (United Health), ReDesign Health (Calibrate), Sanofi, and Scientific Intake; and serves on the steering committee for the SELECT cardiovascular outcome trial for Novo Nordisk’s investigational product semaglutide. P.R.S. is a Board Member and Advisory Panel member for GI Dynamics; has consulted for Ethicon, Medtronic, WL Gore, and BD Surgical; has received research support from Ethicon, NIH, Medtronic, and Pacira; and has equity in SEHQC and LLC. R.J.S. receives research support from Novo Nordisk, Pfizer, Kintai, Ionis, Zafgen, and Astra Zeneca; has received consulting fees from Novo Nordisk, Kintai, Ionis, Sanofi, and Scohia; and has equity in ReDesign Health and Zafgen. T.D. is an employee of Diabetes UK.